| State |
Study Site |
Indication |
Title |
Description |
Details |
| TX |
Texas Oncology-Baylor Charles Sammons Cancer Center |
Metastatic Melanoma |
An Open-Label, Multi-Center Phase II Study of Continuous Oral Dosing of R05185426 in Patients with Metastatic Melanoma, #NP22657 |
View |
| TX |
Texas Oncology-Baylor Charles Sammons Cancer Center |
Renal Cell Carcinoma |
Phase 2 Open-Label Single-Arm, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination with AMG 386 as First Line or Second Line Therapy for Subjects with Metastatic Renal Cell Carcinoma. |
View |
TX
|
Texas Oncology-Bedford ( Edwards Cancer Center )
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
USON-Texas Oncology-Bedford,
USON - Texas Oncology - Klabzuba
|
Brain Cancer |
A Phase II Trial of Hippocampal Avoidance During Whole Brain
Radiotherapy for Brain Metastases |
NCT01227954 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Garland,
Texas Oncology-Grapevine,
Texas Oncology-Kyle,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Breast Cancer |
(CA180-185) Randomized Phase II Trial of Letrozole with or without Dasatinib as First and Second-Line Treatment for Hormone Receptor-Positive, HER2-Negative Post-Menopausal Breast Cancer that is Unresectable, Locally Recurrent or Metastatic |
NCT00696072 |
View |
TX
|
Texas Oncology-Sherman,
Texas Oncology-Abilene,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Grapevine,
Texas Oncology-Kyle,
Texas Oncology-Lewisville,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Mesquite,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Plano East,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler
|
Breast Cancer |
11-PIR-11: The BEACON Study (Breast Cancer Outcomes With Nktr-102): A Phase 3 Open-Label, Randomized, Multicenter Study Of NKTR-102 Versus Treatment Of Physician’s Choice (TPC) In Patients With Locally Recurrent Or Metastatic Breast Cancer Previously Tre |
NCT01492101 |
View |
TX
|
Texas Oncology-Sherman,
Texas Oncology-Arlington South,
Texas Oncology-Bedford ( Edwards Cancer Center )
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Wichita Falls Texoma Cancer Center,
USOR Texas Oncology Houston Memorial City
|
Breast Cancer |
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation and Radiation Alone for Women with Her2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy |
NCT00769379 |
View |
TX
|
Texas Oncology-Bedford ( Edwards Cancer Center )
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
USON-Texas Oncology-Arlington South,
USON-Texas Oncology-Denton,
USON-Texas Oncology-Klabzuba,
USON-Texas Oncology Sugarland,
USON-Texas Oncology Texoma Cancer Center,
USOR Texas Oncology Houston Memorial City
|
Breast Cancer |
A Phase III Trial Of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost For Early-Stage Breast Cancer (RTOG 1005) |
NCT01349322 |
View |
TX
|
Texas Oncology-Sherman,
Texas Oncology-Bedford ( Edwards Cancer Center )
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
Texas Oncology-Sugar Land
|
Breast Cancer |
A Randomized Phase III Study of Conventional Whole Breast
Irradiation (WBI) Versus Partial Breast Irradiation (PBI)
for Women with Stage 0, I, or II Breast Cancer (RTOG 0413) |
NCT00103181 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Garland,
Texas Oncology-Plano West
|
Breast Cancer |
A Randomized, Phase III, Open-label Study of Lapatinib plus Trastuzumab versus Trastuzumab as Continued HER2 Suppression Therapy after Completion of First- or Second-line Trastuzumab plus Chemotherapy in Subjects with HER2-positive Metastatic Breast Cance |
NCT00968968 |
View |
TX
|
Surgical Specialists of Plano (Biopsy),
Texas Breast Specialists (biopsy),
Texas Health Women's Specialty Surgery Center Dallas (Biopsy),
Texas Oncology-Amarillo,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Garland,
Texas Oncology-Grapevine,
Texas Oncology-Kyle,
Texas Oncology-Lewisville,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Texas Breast Specialist,
Texas Oncology-Tyler,
Texas Oncology-Weslaco
|
Breast Cancer |
MM-121-02-02-07:A Randomized, Phase 2 Trial of Preoperative MM-121 with Paclitaxel in HER2-negative Breast Cancer |
NCT01421472 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Grapevine,
Texas Oncology-Memorial City,
Texas Oncology-Tyler
|
Breast Cancer |
Prediction of Response to Neoadjuvant Chemotherapy in Women with Operable Breast Cancer (PT-304)
|
NCT01007890 |
View |
TX
|
Texas Oncology-Sherman,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Plano East,
Texas Oncology-Sugar Land,
Texas Oncology-Weslaco
|
Breast Cancer |
Protocol Number E7389-A001-208: A Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2)Positive Breast Cancer |
NCT01269346 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Tyler
|
Breast Cancer |
Randomized, Open-Label Study of Abiraterone Acetate (JNJ 212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy (212082BCA2001) |
NCT01355770 |
View |
TX
|
Texas Oncology-Sherman,
Texas Oncology-Waco,
Texas Oncology-Abilene,
Texas Oncology-Arlington North,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Garland,
Texas Oncology-Grapevine,
Texas Oncology-Kyle,
Texas Oncology-Lewisville,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Medical City Dallas,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco,
Texas Oncology-Weslaco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Colon Cancer |
Protocol I4T-MC-JVBB (also known as IMCL CP12 0920) A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive Du |
NCT01183780 |
View |
TX
|
Texas Oncology-Sherman,
Texas Oncology-Bedford ( Edwards Cancer Center )
Texas Oncology-Denton South,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
USOR Texas Oncology Houston Memorial City
|
Endometrial Cancer |
GOG 0249- A Phase III Trial of Pelvic Radiation Therapy versus Vaginal Cuff Brachytherapy followed by PACLITAXEL/CARBOPLATIN Chemotherapy in patients with High-Risk, early stage Endometrial Carcinoma
|
NCT00807768 |
View |
TX
|
Texas Oncology-Sherman,
Texas Oncology-Bedford ( Edwards Cancer Center )
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Wichita Falls Texoma Cancer Center,
USOR Texas Oncology Houston Memorial City
|
Esophageal Cancer |
A Phase III Trial Evaluating The Addition Of Cetuximab To Paclitaxel, Cisplatin, And Radiation For Patients With Esophageal Cancer Who Are Treated Without Surgery (RTOG 0436)
|
NCT00655876 |
View |
TX
|
Texas Oncology-Sherman,
Texas Oncology-Bedford ( Edwards Cancer Center )
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
Texas Oncology-Sugar Land,
Texas Oncology-Wichita Falls Texoma Cancer Center,
USOR Texas Oncology Houston Memorial City
|
Head and Neck Cancer |
A PHASE III STUDY OF POSTOPERATIVE RADIATION THERAPY (IMRT) +/- CETUXIMAB FOR LOCALLY-ADVANCED RESECTED HEAD AND NECK CANCER (RTOG 0920) |
NCT00956007 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Cedar Park,
Texas Oncology-Kyle,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin
|
Head and Neck Cancer |
Phase 1/2 Study of PX-866 and docetaxel in patients with solid tumors (PX-866-002) |
NCT01204099 |
View |
TX
|
Texas Oncology-Waco,
Texas Oncology-Amarillo,
Texas Oncology-Bedford,
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Grapevine,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
ITP |
IM-T-hA20-07: A Phase I/II Study of Immunotherapy with Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Adult Patients with Chronic Immune Thrombocytopenia Purpura |
NCT00547066 |
View |
TX
|
Texas Oncology-Rockwall,
Texas Oncology-Waco,
Texas Oncology-Amarillo,
Texas Oncology-Arlington North,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Kyle,
Texas Oncology-Lewisville,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Medical City Dallas,
Texas Oncology-Mesquite,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Plano East,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Waco,
Texas Oncology-Weslaco
|
Leukemia |
CA180330: Studying Interventions for Managing Patients with Chronic Myeloid Leukemia in Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY) |
NCT01244750 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Lewisville,
Texas Oncology-Medical City Dallas,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Leukemia |
SGN35-013: A Phase 2, open-label, single-arm study of brentuximab vedotin in patients with CD30-positive nonlymphomatous malignancies |
NCT01461538 |
View |
TX
|
Texas Oncology-Sherman,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford ( Edwards Cancer Center )
Texas Oncology-Cedar Park,
Texas Oncology-Kyle,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Sugar Land,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Lung Cancer |
(H3E-MC-JMIG): Phase 3 Study of Pemetrexed, Cisplatin,and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Adv |
NCT00686959 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Cedar Park,
Texas Oncology-Kyle,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin
|
Lung Cancer |
(MEK114653) A Phase II, Open-label, Multicenter, Randomized Study to
Assess the Efficacy and Safety of GSK1120212 Compared with
Docetaxel in 2nd Line Subjects with Targeted Mutations (KRAS,
NRAS, BRAF, MEK1) in Locally Advanced or Metastatic Non-small
|
NCT01362296 |
View |
TX
|
Texas Oncology-Arlington North,
Texas Oncology-Arlington South,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Tyler
|
Lung Cancer |
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients with Stage IIIB or IV Non-Small Cell Lung Cancer (IPI-504-14) |
NCT01362400 |
View |
TX
|
Texas Oncology-Sherman,
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Garland,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Medical City Dallas,
Texas Oncology-Mesquite,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Plano West,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco,
Texas Oncology-Weslaco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Lung Cancer |
Amgen Protocol 20070782: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Rec |
NCT00858364 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Cedar Park,
Texas Oncology-Kyle,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin
|
Lung Cancer |
An open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway (CBKM120D2201) |
NCT01297491 |
View |
TX
|
Texas Oncology-Waco,
Texas Oncology-Garland,
Texas Oncology-Paris,
Texas Oncology-Plano West,
Texas Oncology-Waco
|
Lung Cancer |
E7080-703: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) versus BSC Alone in Patients with Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at L |
NCT01529112 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Cedar Park,
Texas Oncology-Kyle,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin
|
Lung Cancer |
Phase 1/2 Study of PX-866 and docetaxel in patients with solid tumors (PX-866-002) |
NCT01204099 |
View |
TX
|
Texas Oncology-El Paso Cancer Treatment Center Joe Battle,
Texas Oncology-Sherman,
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Grapevine,
Texas Oncology-Lewisville,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Medical City Dallas,
Texas Oncology-Mesquite,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Weslaco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Lung Cancer |
Protocol I4T-MC-JVBA (also known as IMCL CP12-1027) A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior P |
NCT01168973 |
View |
TX
|
Texas Oncology-El Paso Cancer Treatment Center Joe Battle,
Texas Oncology-Waco,
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Grapevine,
Texas Oncology-Longview Cancer Center,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco,
Texas Oncology-Weslaco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Lung Cancer |
Protocol IMCL CP12-0917: An Open-label, Multicenter, Randomized, Phase 2 Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination with Platinum-based Chemotherapy versus Platinum-based Chemotherapy Alone as First-line Treatm |
NCT01160744 |
View |
TX
|
Texas Oncology-Sherman,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Lymphomas |
OFB114612: Phase II Open-Label Study of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL) Which Has Relapsed after Rituximab Therapy |
NCT01294579 |
View |
TX
|
Texas Oncology-Waco,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Waco,
Texas Oncology-Weslaco
|
Lymphomas |
PIX306: A Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem C |
NCT01321541 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Cedar Park,
Texas Oncology-Kyle,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Tyler,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Lymphomas |
Protocol C05013 - An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma |
NCT00931918 |
View |
TX
|
Texas Oncology-Sherman,
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Denton South,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Garland,
Texas Oncology-Lewisville,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Mesquite,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Plano East,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Lymphomas |
SGN35-012: A phase 2 study of brentuximab vedotin in relapsed or refractory CD30-positive non-Hodgkin lymphoma (NHL) |
NCT01421667 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Grapevine
|
Melanoma |
(E7080-G000-206): An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma |
NCT01136967 |
View |
TX
|
Texas Oncology-Amarillo,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Tyler
|
Myelodysplastic Syndrome |
A multi-center, randomized, double-blind, placebo-controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload (TELESTO)
Protocol Number: CICL670A2302 |
NCT00940602 |
View |
TX
|
Texas Oncology-Waco,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Garland,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Myelomas |
A prospective, longitudinal, observational study in newly diagnosed multiple myeloma (MM) patients to assess the relationship between patient outcomes, treatment regimens and molecular profiles (MMRF–11–001) |
NCT01454297 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Grapevine,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler
|
Myelomas |
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib (Perifosine 339) |
NCT01002248 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Lewisville,
Texas Oncology-Medical City Dallas,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Myelomas |
SGN35-013: A Phase 2, open-label, single-arm study of brentuximab vedotin in patients with CD30-positive nonlymphomatous malignancies |
NCT01461538 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Grapevine,
Texas Oncology-South Austin
|
Ovarian Cancer |
20101129(TRINOVA-3): A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube C |
NCT01493505 |
View |
TX
|
Brooks Hearing and Speech Clinic (Audiology Exam Only),
Texas Oncology-Paris
|
Pancreatic Cancer |
20060540: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination with Gemcitabine as First-line Therapy for Metastatic Adenocarcinoma of the Pancreas |
NCT01231347 |
View |
TX
|
Texas Oncology-Bedford ( Edwards Cancer Center )
Texas Oncology-Klabzuba,
USON-Texas Oncology-Longview Cancer Center,
USON-Texas Oncology-Sherman,
USON-Texas Oncology-Tyler,
USON-Texas Oncology Sugarland,
USOR Texas Oncology Houston Memorial City
|
Pancreatic Cancer |
A Phase III Trial Evaluating both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma (RTOG 0848) |
NCT01013649 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center
|
Prostate Cancer |
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men with Metastatic Castrate-Resistant Prostate Cancer (10TASQ10) |
NCT01234311 |
View |
TX
|
Texas Oncology-Sherman,
Texas Oncology-Bedford ( Edwards Cancer Center )
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Sugar Land,
Texas Oncology-Wichita Falls Texoma Cancer Center,
USOR Texas Oncology Houston Memorial City
|
Prostate Cancer |
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer RTOG 0815 |
NCT00936390 |
View |
TX
|
Texas Oncology-Sherman,
Texas Oncology-Bedford ( Edwards Cancer Center )
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
Texas Oncology-Lewisville,
Texas Oncology-Longview Cancer Center,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Wichita Falls Texoma Cancer Center,
USOR Texas Oncology Houston Memorial City
|
Prostate Cancer |
A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (Spport) In Prostate Cancer Patients With A Rising Psa After Radical Prostatectomy (RTOG 0534) |
NCT00567580 |
View |
TX
|
Texas Oncology-Bedford,
Texas Oncology-Grapevine,
Texas Oncology-Tyler
|
Prostate Cancer |
BNIT-PRV-301: A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +\- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer |
NCT01322490 |
View |
TX
|
Texas Oncology-El Paso Cancer Treatment Center Joe Battle,
Texas Oncology-Sherman,
Texas Oncology-Abilene,
Texas Oncology-Arlington North,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Denton South,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Kyle,
Texas Oncology-Lewisville,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land
|
Prostate Cancer |
P10-3: A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer |
NCT01306890 |
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Grapevine,
Texas Oncology-Kyle,
Texas Oncology-Memorial City,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Tyler
|
Renal Cancer |
(CTKI258A2302): An open-label, randomized, multi-center, Phase III study to compare the safety and efficacy of TKI258 versus sorafenib
in patients with metastatic renal cell carcinoma after failure
of anti-angiogenic (VEGF-targeted and mTOR inhibitor) t |
NCT01223027 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Grapevine,
Texas Oncology-Memorial City,
Texas Oncology-Tyler
|
Renal Cancer |
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy (VEG113387) |
NCT01235962 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Tyler
|
Renal Cancer |
B1131004:Phase II Trial of PF-04856884 (CVX-060), A Selective Angiopoietin-2 (ANG-2) Inhibitor in Combination with AG-013736 (Axitinib) in Patients with Previously Treated Metastatic Renal Cell Carcinoma |
NCT01441414 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Grapevine,
Texas Oncology-Medical City Dallas
|
Sarcoma |
IPM3001: A Phase III multicenter, international, randomized, double-blind, placebo-controlled study of doxorubicin plus palifosfamide-tris vs. doxorubicin plus placebo in patients with front-line metastatic soft tissue sarcoma |
NCT01168791 |
View |
TX
|
Texas Oncology-Sherman,
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Denton South,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Garland,
Texas Oncology-Lewisville,
Texas Oncology-Longview Cancer Center,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Mesquite,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Skin Cancer |
A phase II, randomized double-blind study of efficacy and
safety of two dose levels of LDE225 in patients with locally
advanced or metastatic basal cell carcinoma (CLDE225A2201) |
NCT01327053 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Tyler
|
Solid Tumors |
(MEK113486): A Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination with Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or nab-Paclitaxel in Subjects with Adva |
NCT01192165 |
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Tyler
|
Solid Tumors |
A Phase 1 and Pharmacologic Study of MM-111 in Combination with Multiple Treatment Regimens in Patients with Advanced HER2 Positive Solid Tumors (MM-111-01-01-03) |
NCT01304784 |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Lewisville,
Texas Oncology-Medical City Dallas,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Solid Tumors |
SGN35-013: A Phase 2, open-label, single-arm study of brentuximab vedotin in patients with CD30-positive nonlymphomatous malignancies |
NCT01461538 |
View |
TX
|
Texas Oncology-Sherman,
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Beaumont ( Mamie McFaddin Ward Cancer Center )
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Garland,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Medical City Dallas,
Texas Oncology-Mesquite,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Plano West,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco,
Texas Oncology-Weslaco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Supportive Care |
Amgen Protocol 20070782: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Rec |
NCT00858364 |
View |
TX
|
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler
|
Thromboses/Coagulation |
Protocol DU-176b-D-U305: A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects with Symptomatic D |
NCT00986154 |
View |